SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) today announced that it has initiated a relationship with Kentucky Bioprocessing LLC to establish processes to support large-scale production of the active affinity agents immobilized within the Aethlon Hemopurifier(R). Such affinity agents allow the Hemopurifer(R) to selectively capture a broad-spectrum of viruses from blood and other fluids. The Hemopurifier(R) is the first-in-class medical device to selectively adsorb viruses and immunosuppressive particles from the bloodstream.
"The relationship with Kentucky Bioprocessing represents an important step towards establishing the long-term commercial feasibility of our Hemopurifier(R), stated Aethlon Medical CEO, Jim Joyce. "Beyond a significant cost reduction of our affinity agents, the relationship offers large yield production potential in time frames that could improve our response capability against viral outbreaks, including unforeseen bioterror and pandemic threats," concluded Joyce.
As part of the relationship, Kentucky Bioprocessing will establish and confirm the sequence of Aethlon's affinity agents and then conduct optimization studies to insure agent purity. The affinity agents will then be transported as cloned proteins to be expressed in and extracted from tobacco plants as a strategy to maximize production yields.
About Kentucky Bioprocessing LLC
Kentucky Bioprocessing (KBP) is a service provider in the biotechnology industry specializing in the expression, extraction and purification of proteins and other high value products from plants. We work with clients to develop and implement scalable and regulatory compliant production processes designed to result in commercially viable end products. Operating from our one of a kind facility located in Owensboro, Kentucky KBP combines a robust intellectual property portfolio with a professional team experienced in successfully producing dozens of proteins in both stable transgenic and transient plant based gene expression systems. Whether you are considering an expression method for a target protein or are in need of process development and production services, our experience and know how can help you to avoid costly and time consuming mistakes and speed the commercialization process. Additional information is available online at www.kbpllc.com
About Aethlon Medical
Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.
Contacts: Jon Cunningham RedChip Companies Inc. (407) 644-4256 (407) 491-4498 -cell www.redchip.com Jon@redchip.com Jim Joyce Chairman, CEO 858.459.7800 x301 email@example.com Jim Frakes Senior VP Finance 858.459.7800 x300 firstname.lastname@example.org
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier(R) to reduce viral loads and other disease conditions, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the capability to grow cloned affinity agents within projected costs and timeframes, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
|SOURCE Aethlon Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved